Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies

Marcelo C. Pasquini, Mei Jie Zhang, Bruno C. Medeiros, Philippe Armand, Zhen Huan Hu, Taiga Nishihori, Mahmoud D. Aljurf, Görgün Akpek, Jean Yves Cahn, Mitchell S. Cairo, Jan Cerny, Edward A. Copelan, Abhinav Deol, César O. Freytes, Robert Peter Gale, Siddhartha Ganguly, Biju George, Vikas Gupta, Gregory A. Hale, Rammurti T. KambleThomas R. Klumpp, Hillard M. Lazarus, Selina M. Luger, Jane L. Liesveld, Mark R. Litzow, David I. Marks, Rodrigo Martino, Maxim Norkin, Richard F. Olsson, Betul Oran, Attaphol Pawarode, Michael A. Pulsipher, Muthalagu Ramanathan, Ran Reshef, Ayman A. Saad, Wael Saber, Bipin N. Savani, Harry C. Schouten, Olle Ringdén, Martin S. Tallman, Geoffrey L. Uy, William A. Wood, Baldeep Wirk, Waleska S. Pérez, Minoo Batiwalla, Daniel J. Weisdorf

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The presence of monosomal karyotype (MK+) in acute myeloid leukemia (AML) is associated with dismal outcomes. We evaluated the impact of MK+ in AML (MK+AML, n = 240) and in myelodysplastic syndrome (MDS) (MK+MDS, n = 221) on hematopoietic cell transplantation outcomes compared with other cytogenetically defined groups (AML, n = 3360; MDS, n = 1373) as reported to the Center for International Blood and Marrow Transplant Research from 1998 to 2011. MK+ AML was associated with higher disease relapse (hazard ratio, 1.98; P <.01), similar transplantation-related mortality (TRM) (hazard ratio, 1.01; P =90), and worse survival (hazard ratio, 1.67; P <.01) compared with those outcomes for other cytogenetically defined AML. Among patients with MDS, MK+ MDS was associated with higher disease relapse (hazard ratio, 2.39; P <.01), higher TRM (hazard ratio, 1.80; P <.01), and worse survival (HR, 2.02; P <.01). Subset analyses comparing chromosome 7 abnormalities (del7/7q) with or without MK+ demonstrated higher mortality for MK+ disease in for both AML (hazard ratio, 1.72; P <.01) and MDS (hazard ratio, 1.79; P <.01). The strong negative impact of MK+ in myeloid malignancies was observed in all age groups and using either myeloablative or reduced-intensity conditioning regimens. Alternative approaches to mitigate disease relapse in this population are needed.

Original languageEnglish (US)
Pages (from-to)248-257
Number of pages10
JournalBiology of Blood and Marrow Transplantation
Volume22
Issue number2
DOIs
StatePublished - Feb 1 2016

Fingerprint

Cell Transplantation
Karyotype
Acute Myeloid Leukemia
Myelodysplastic Syndromes
Neoplasms
Recurrence
Mortality
Transplantation
Chromosomes, Human, Pair 7
Survival
Chromosome Aberrations
Age Groups
Bone Marrow
Transplants
Research
Population

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

Cite this

Pasquini, M. C., Zhang, M. J., Medeiros, B. C., Armand, P., Hu, Z. H., Nishihori, T., ... Weisdorf, D. J. (2016). Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. Biology of Blood and Marrow Transplantation, 22(2), 248-257. https://doi.org/10.1016/j.bbmt.2015.08.024
Pasquini, Marcelo C. ; Zhang, Mei Jie ; Medeiros, Bruno C. ; Armand, Philippe ; Hu, Zhen Huan ; Nishihori, Taiga ; Aljurf, Mahmoud D. ; Akpek, Görgün ; Cahn, Jean Yves ; Cairo, Mitchell S. ; Cerny, Jan ; Copelan, Edward A. ; Deol, Abhinav ; Freytes, César O. ; Gale, Robert Peter ; Ganguly, Siddhartha ; George, Biju ; Gupta, Vikas ; Hale, Gregory A. ; Kamble, Rammurti T. ; Klumpp, Thomas R. ; Lazarus, Hillard M. ; Luger, Selina M. ; Liesveld, Jane L. ; Litzow, Mark R. ; Marks, David I. ; Martino, Rodrigo ; Norkin, Maxim ; Olsson, Richard F. ; Oran, Betul ; Pawarode, Attaphol ; Pulsipher, Michael A. ; Ramanathan, Muthalagu ; Reshef, Ran ; Saad, Ayman A. ; Saber, Wael ; Savani, Bipin N. ; Schouten, Harry C. ; Ringdén, Olle ; Tallman, Martin S. ; Uy, Geoffrey L. ; Wood, William A. ; Wirk, Baldeep ; Pérez, Waleska S. ; Batiwalla, Minoo ; Weisdorf, Daniel J. / Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. In: Biology of Blood and Marrow Transplantation. 2016 ; Vol. 22, No. 2. pp. 248-257.
@article{8184732ef86645c597fcc0904102cfa3,
title = "Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies",
abstract = "The presence of monosomal karyotype (MK+) in acute myeloid leukemia (AML) is associated with dismal outcomes. We evaluated the impact of MK+ in AML (MK+AML, n = 240) and in myelodysplastic syndrome (MDS) (MK+MDS, n = 221) on hematopoietic cell transplantation outcomes compared with other cytogenetically defined groups (AML, n = 3360; MDS, n = 1373) as reported to the Center for International Blood and Marrow Transplant Research from 1998 to 2011. MK+ AML was associated with higher disease relapse (hazard ratio, 1.98; P <.01), similar transplantation-related mortality (TRM) (hazard ratio, 1.01; P =90), and worse survival (hazard ratio, 1.67; P <.01) compared with those outcomes for other cytogenetically defined AML. Among patients with MDS, MK+ MDS was associated with higher disease relapse (hazard ratio, 2.39; P <.01), higher TRM (hazard ratio, 1.80; P <.01), and worse survival (HR, 2.02; P <.01). Subset analyses comparing chromosome 7 abnormalities (del7/7q) with or without MK+ demonstrated higher mortality for MK+ disease in for both AML (hazard ratio, 1.72; P <.01) and MDS (hazard ratio, 1.79; P <.01). The strong negative impact of MK+ in myeloid malignancies was observed in all age groups and using either myeloablative or reduced-intensity conditioning regimens. Alternative approaches to mitigate disease relapse in this population are needed.",
author = "Pasquini, {Marcelo C.} and Zhang, {Mei Jie} and Medeiros, {Bruno C.} and Philippe Armand and Hu, {Zhen Huan} and Taiga Nishihori and Aljurf, {Mahmoud D.} and G{\"o}rg{\"u}n Akpek and Cahn, {Jean Yves} and Cairo, {Mitchell S.} and Jan Cerny and Copelan, {Edward A.} and Abhinav Deol and Freytes, {C{\'e}sar O.} and Gale, {Robert Peter} and Siddhartha Ganguly and Biju George and Vikas Gupta and Hale, {Gregory A.} and Kamble, {Rammurti T.} and Klumpp, {Thomas R.} and Lazarus, {Hillard M.} and Luger, {Selina M.} and Liesveld, {Jane L.} and Litzow, {Mark R.} and Marks, {David I.} and Rodrigo Martino and Maxim Norkin and Olsson, {Richard F.} and Betul Oran and Attaphol Pawarode and Pulsipher, {Michael A.} and Muthalagu Ramanathan and Ran Reshef and Saad, {Ayman A.} and Wael Saber and Savani, {Bipin N.} and Schouten, {Harry C.} and Olle Ringd{\'e}n and Tallman, {Martin S.} and Uy, {Geoffrey L.} and Wood, {William A.} and Baldeep Wirk and P{\'e}rez, {Waleska S.} and Minoo Batiwalla and Weisdorf, {Daniel J.}",
year = "2016",
month = "2",
day = "1",
doi = "10.1016/j.bbmt.2015.08.024",
language = "English (US)",
volume = "22",
pages = "248--257",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "2",

}

Pasquini, MC, Zhang, MJ, Medeiros, BC, Armand, P, Hu, ZH, Nishihori, T, Aljurf, MD, Akpek, G, Cahn, JY, Cairo, MS, Cerny, J, Copelan, EA, Deol, A, Freytes, CO, Gale, RP, Ganguly, S, George, B, Gupta, V, Hale, GA, Kamble, RT, Klumpp, TR, Lazarus, HM, Luger, SM, Liesveld, JL, Litzow, MR, Marks, DI, Martino, R, Norkin, M, Olsson, RF, Oran, B, Pawarode, A, Pulsipher, MA, Ramanathan, M, Reshef, R, Saad, AA, Saber, W, Savani, BN, Schouten, HC, Ringdén, O, Tallman, MS, Uy, GL, Wood, WA, Wirk, B, Pérez, WS, Batiwalla, M & Weisdorf, DJ 2016, 'Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies', Biology of Blood and Marrow Transplantation, vol. 22, no. 2, pp. 248-257. https://doi.org/10.1016/j.bbmt.2015.08.024

Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. / Pasquini, Marcelo C.; Zhang, Mei Jie; Medeiros, Bruno C.; Armand, Philippe; Hu, Zhen Huan; Nishihori, Taiga; Aljurf, Mahmoud D.; Akpek, Görgün; Cahn, Jean Yves; Cairo, Mitchell S.; Cerny, Jan; Copelan, Edward A.; Deol, Abhinav; Freytes, César O.; Gale, Robert Peter; Ganguly, Siddhartha; George, Biju; Gupta, Vikas; Hale, Gregory A.; Kamble, Rammurti T.; Klumpp, Thomas R.; Lazarus, Hillard M.; Luger, Selina M.; Liesveld, Jane L.; Litzow, Mark R.; Marks, David I.; Martino, Rodrigo; Norkin, Maxim; Olsson, Richard F.; Oran, Betul; Pawarode, Attaphol; Pulsipher, Michael A.; Ramanathan, Muthalagu; Reshef, Ran; Saad, Ayman A.; Saber, Wael; Savani, Bipin N.; Schouten, Harry C.; Ringdén, Olle; Tallman, Martin S.; Uy, Geoffrey L.; Wood, William A.; Wirk, Baldeep; Pérez, Waleska S.; Batiwalla, Minoo; Weisdorf, Daniel J.

In: Biology of Blood and Marrow Transplantation, Vol. 22, No. 2, 01.02.2016, p. 248-257.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies

AU - Pasquini, Marcelo C.

AU - Zhang, Mei Jie

AU - Medeiros, Bruno C.

AU - Armand, Philippe

AU - Hu, Zhen Huan

AU - Nishihori, Taiga

AU - Aljurf, Mahmoud D.

AU - Akpek, Görgün

AU - Cahn, Jean Yves

AU - Cairo, Mitchell S.

AU - Cerny, Jan

AU - Copelan, Edward A.

AU - Deol, Abhinav

AU - Freytes, César O.

AU - Gale, Robert Peter

AU - Ganguly, Siddhartha

AU - George, Biju

AU - Gupta, Vikas

AU - Hale, Gregory A.

AU - Kamble, Rammurti T.

AU - Klumpp, Thomas R.

AU - Lazarus, Hillard M.

AU - Luger, Selina M.

AU - Liesveld, Jane L.

AU - Litzow, Mark R.

AU - Marks, David I.

AU - Martino, Rodrigo

AU - Norkin, Maxim

AU - Olsson, Richard F.

AU - Oran, Betul

AU - Pawarode, Attaphol

AU - Pulsipher, Michael A.

AU - Ramanathan, Muthalagu

AU - Reshef, Ran

AU - Saad, Ayman A.

AU - Saber, Wael

AU - Savani, Bipin N.

AU - Schouten, Harry C.

AU - Ringdén, Olle

AU - Tallman, Martin S.

AU - Uy, Geoffrey L.

AU - Wood, William A.

AU - Wirk, Baldeep

AU - Pérez, Waleska S.

AU - Batiwalla, Minoo

AU - Weisdorf, Daniel J.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - The presence of monosomal karyotype (MK+) in acute myeloid leukemia (AML) is associated with dismal outcomes. We evaluated the impact of MK+ in AML (MK+AML, n = 240) and in myelodysplastic syndrome (MDS) (MK+MDS, n = 221) on hematopoietic cell transplantation outcomes compared with other cytogenetically defined groups (AML, n = 3360; MDS, n = 1373) as reported to the Center for International Blood and Marrow Transplant Research from 1998 to 2011. MK+ AML was associated with higher disease relapse (hazard ratio, 1.98; P <.01), similar transplantation-related mortality (TRM) (hazard ratio, 1.01; P =90), and worse survival (hazard ratio, 1.67; P <.01) compared with those outcomes for other cytogenetically defined AML. Among patients with MDS, MK+ MDS was associated with higher disease relapse (hazard ratio, 2.39; P <.01), higher TRM (hazard ratio, 1.80; P <.01), and worse survival (HR, 2.02; P <.01). Subset analyses comparing chromosome 7 abnormalities (del7/7q) with or without MK+ demonstrated higher mortality for MK+ disease in for both AML (hazard ratio, 1.72; P <.01) and MDS (hazard ratio, 1.79; P <.01). The strong negative impact of MK+ in myeloid malignancies was observed in all age groups and using either myeloablative or reduced-intensity conditioning regimens. Alternative approaches to mitigate disease relapse in this population are needed.

AB - The presence of monosomal karyotype (MK+) in acute myeloid leukemia (AML) is associated with dismal outcomes. We evaluated the impact of MK+ in AML (MK+AML, n = 240) and in myelodysplastic syndrome (MDS) (MK+MDS, n = 221) on hematopoietic cell transplantation outcomes compared with other cytogenetically defined groups (AML, n = 3360; MDS, n = 1373) as reported to the Center for International Blood and Marrow Transplant Research from 1998 to 2011. MK+ AML was associated with higher disease relapse (hazard ratio, 1.98; P <.01), similar transplantation-related mortality (TRM) (hazard ratio, 1.01; P =90), and worse survival (hazard ratio, 1.67; P <.01) compared with those outcomes for other cytogenetically defined AML. Among patients with MDS, MK+ MDS was associated with higher disease relapse (hazard ratio, 2.39; P <.01), higher TRM (hazard ratio, 1.80; P <.01), and worse survival (HR, 2.02; P <.01). Subset analyses comparing chromosome 7 abnormalities (del7/7q) with or without MK+ demonstrated higher mortality for MK+ disease in for both AML (hazard ratio, 1.72; P <.01) and MDS (hazard ratio, 1.79; P <.01). The strong negative impact of MK+ in myeloid malignancies was observed in all age groups and using either myeloablative or reduced-intensity conditioning regimens. Alternative approaches to mitigate disease relapse in this population are needed.

UR - http://www.scopus.com/inward/record.url?scp=84958573214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958573214&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2015.08.024

DO - 10.1016/j.bbmt.2015.08.024

M3 - Article

C2 - 26327629

AN - SCOPUS:84958573214

VL - 22

SP - 248

EP - 257

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 2

ER -